Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Oxford Nanopore’s Trial Win Over DNA Sequencing Patents Upheld

May 11, 2021, 7:04 PM

Oxford Nanopore’s reference at trial to the then-emerging coronavirus pandemic doesn’t warrant a new trial, the Federal Circuit found, upholding a jury verdict that invalidated parts of two Pacific Biosciences patents on DNA-sequencing technology.

The U.S. Court of Appeals for the Federal Circuit also said substantial evidence supports the jury’s finding that it would take undue experimentation to achieve the full scope of sequencing methods claimed in Pacific Biosciences of California Inc. patents.

PacBio accused Oxford Nanopore Technologies Inc. of “outrageous exploitation of a world health crisis” and improperly suggesting during opening statements that PacBio was trying to block products ...